In 2017, WHO, PATH, the Bill & Melinda Gates Foundation, UNICEF and Gavi launched the Vaccine Innovation Prioritisation Strategy (VIPS), with the aim to drive vaccine product innovation to better meet country needs and support Alliance goals on immunisation coverage and equity. Product innovation refers to completely new vaccine products or adaptations to existing products that provide measurable financial or programmatic benefits to low and middle income countries (LMICs), such as increased coverage and equity (e.g., by overcoming a ‘last mile’ barrier) or improved vaccine effectiveness. Through VIPS, the Alliance strives to understand countries’ needs to consider the financial and non-financial impact of innovations; develop common principles to measure the benefits of product innovations; and convene a platform to articulate a clear and aligned perspective on priority product innovations in development and communicate these priorities to provide greater clarity for manufacturers or partners to help inform investment decisions.
At this stage of the VIPS process, we would like to ask for feedback through this survey on the relative importance of immunisation programme implementation challenges and barriers to improved coverage and equity and other pressing issues, from a country perspective. Your answers will inform VIPS assessments of vaccine product innovations in order to prioritise innovations that may be most valued in addressing country needs.
This survey should take no more than 15 minutes to complete and will be available through the 30th September 2018 under one of the following links:
English version - https://www.surveymonkey.com/r/BPMTGC9
French version - https://www.surveymonkey.com/r/LFH2DKQ
Russian version - https://ru.surveymonkey.com/r/R3XMMMC
Please feel free to forward the survey links to other stakeholders who may be interested.
We apologise for the inconvenience if you have already received a link to this survey through another communication.
We appreciate you making time to complete this questionnaire and look forward to continuing engagment with you on this important topic. If you have any questions, please feel free to contact Anna Osborne: email@example.com
Debbie Kristensen on behalf of the VIPS Secretariat